Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 5/6 |
DVLA Stock Overview
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally.
Darya-Varia Laboratoria Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | Rp2,440.00 |
52 Week High | Rp3,400.00 |
52 Week Low | Rp2,250.00 |
Beta | -0.0098 |
1 Month Change | -11.27% |
3 Month Change | -18.12% |
1 Year Change | 5.63% |
3 Year Change | 8.93% |
5 Year Change | 16.75% |
Change since IPO | 187.06% |
Recent News & Updates
Shareholder Returns
DVLA | ID Pharmaceuticals | ID Market | |
---|---|---|---|
7D | -0.4% | -0.4% | -1.0% |
1Y | 5.6% | 1.5% | 18.2% |
Return vs Industry: DVLA exceeded the ID Pharmaceuticals industry which returned 1.5% over the past year.
Return vs Market: DVLA underperformed the ID Market which returned 18.2% over the past year.
Price Volatility
DVLA volatility | |
---|---|
DVLA Average Weekly Movement | 3.7% |
Pharmaceuticals Industry Average Movement | 3.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in ID Market | 12.2% |
10% least volatile stocks in ID Market | 3.0% |
Stable Share Price: DVLA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: DVLA's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 1,239 | Jose Romana | https://www.darya-varia.com |
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas.
Darya-Varia Laboratoria Fundamentals Summary
DVLA fundamental statistics | |
---|---|
Market Cap | Rp2.73t |
Earnings (TTM) | Rp146.73b |
Revenue (TTM) | Rp1.90t |
18.6x
P/E Ratio1.4x
P/S RatioIs DVLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DVLA income statement (TTM) | |
---|---|
Revenue | Rp1.90t |
Cost of Revenue | Rp905.76b |
Gross Profit | Rp995.13b |
Other Expenses | Rp848.41b |
Earnings | Rp146.73b |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
Earnings per share (EPS) | 131.01 |
Gross Margin | 52.35% |
Net Profit Margin | 7.72% |
Debt/Equity Ratio | 1.7% |
How did DVLA perform over the long term?
See historical performance and comparisonDividends
4.6%
Current Dividend Yield85%
Payout RatioValuation
Is Darya-Varia Laboratoria undervalued compared to its fair value and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DVLA (IDR2440) is trading below our estimate of fair value (IDR12887.84)
Significantly Below Fair Value: DVLA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DVLA is good value based on its PE Ratio (18.6x) compared to the ID Pharmaceuticals industry average (20.9x).
PE vs Market: DVLA is good value based on its PE Ratio (18.6x) compared to the ID market (18.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DVLA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DVLA is good value based on its PB Ratio (2x) compared to the ID Pharmaceuticals industry average (2.4x).
Future Growth
How is Darya-Varia Laboratoria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
15.4%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Darya-Varia Laboratoria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Darya-Varia Laboratoria performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
3.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DVLA has high quality earnings.
Growing Profit Margin: DVLA's current net profit margins (7.7%) are lower than last year (8.9%).
Past Earnings Growth Analysis
Earnings Trend: DVLA's earnings have grown by 3.9% per year over the past 5 years.
Accelerating Growth: DVLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DVLA had negative earnings growth (-9.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.8%).
Return on Equity
High ROE: DVLA's Return on Equity (10.6%) is considered low.
Financial Health
How is Darya-Varia Laboratoria's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: DVLA's short term assets (IDR1,526.7B) exceed its short term liabilities (IDR595.1B).
Long Term Liabilities: DVLA's short term assets (IDR1,526.7B) exceed its long term liabilities (IDR110.0B).
Debt to Equity History and Analysis
Debt Level: DVLA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if DVLA's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: DVLA's debt is well covered by operating cash flow (1894.3%).
Interest Coverage: DVLA earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Darya-Varia Laboratoria current dividend yield, its reliability and sustainability?
Dividend Score
4/6Dividend Score 4/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
4.59%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DVLA's dividend (4.59%) is higher than the bottom 25% of dividend payers in the ID market (1.12%).
High Dividend: DVLA's dividend (4.59%) is in the top 25% of dividend payers in the ID market (4.1%)
Stability and Growth of Payments
Stable Dividend: DVLA's dividend payments have been volatile in the past 10 years.
Growing Dividend: DVLA's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: At its current payout ratio (85.5%), DVLA's payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (35.8%), DVLA's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
7.3yrs
Average board tenure
CEO
Jose Romana (59 yo)
1.58yrs
Tenure
Mr. Jose Sumpaico Romana has been President Director and Director at PT Darya-Varia Laboratoria Tbk since October 20, 2020. Mr. Romana served as Vice President Director and Director at PT Darya-Varia Labor...
Board Members
Experienced Board: DVLA's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
PT Darya-Varia Laboratoria Tbk's employee growth, exchange listings and data sources
Key Information
- Name: PT Darya-Varia Laboratoria Tbk
- Ticker: DVLA
- Exchange: IDX
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Rp2.733t
- Shares outstanding: 1.12b
- Website: https://www.darya-varia.com
Number of Employees
Location
- PT Darya-Varia Laboratoria Tbk
- Tower C
- South Quarter
- Jakarta
- Jakarta Raya
- 12430
- Indonesia
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/19 00:00 |
End of Day Share Price | 2022/05/19 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.